Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Idasanutlin differential expression in MOLM13 and OCIAML3

ABSTRACT: Idasanutlin differential expression in MOLM13 and OCIAML3

PROVIDER: PRJNA1005281 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR25634306.fastq.gz	Fastqsanger.gz
	SRR25634307.fastq.gz	Fastqsanger.gz
	SRR25634308.fastq.gz	Fastqsanger.gz
	SRR25634309.fastq.gz	Fastqsanger.gz
	SRR25634310.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 8

Similar Datasets

Idasanutlin differential expression in MOLM13 and OCIAML3

Project description:Targeting MDM2 is an attractive therapeutic approach for TP53 wild-type (WT) tumors, including the majority of de novo acute myeloid leukemia (AML) cases. However, patients with WT TP53 have shown variable responses to MDM2 inhibitors in clinical trials, highlighting the need to identify additional biomarkers to maximize the chances of clinical success. We performed CRISPR-Cas9 knockout screens to identify genes that confer resistance to an MDM2 inhibitor idasanutlin. We did not find recurrent sgRNA hits or mutations in p53 downstream targets, such as CDKN1A, BAX, PMIAP1, and BBC3, apart from TP53. This was consistent with the results of individual knockout validation experiments and exome sequencing data from idasanutlin resistant cell lines generated form long-term exposure to low doses of idasanutlin. RNA-seq differential expression analysis revealed that major p53 downstream targets were upregulated in both idasanutlin-sensitive MOLM13 and resistant OCIAML3 cell lines after idasanutlin treatment. These findings highlight the pleiotropic functions of TP53 and suggest that the loss of individual downstream targets of TP53 does not significantly contribute to MDM2 inhibitor resistance.

2024-08-15 | GSE240805 | GEO

Genome-wide CRISPR screen of MOLM13 cells after Idasanutlin treatment

2024-08-15 | GSE240977 | GEO

Genome-wide CRISPR screen of MOLM13 cells after Idasanutlin treatment

Project description:Genome-wide CRISPR screen of MOLM13 cells after Idasanutlin treatment

| PRJNA1005974 | ENA

RNA-seq identifies differential expressed genes upon YTHDC1 knockdown in MOLM13 human acute myeloid leukemia cells

Project description:The goal of this study is to identify differential expressed genes upon YTHDC1 depletion in MOLM13 cells(AML).

2021-05-24 | GSE168565 | GEO

miCLIP, RNA-Seq, and Ribo-Seq in MOLM13 cells

Project description:We studied the following conditions: m6A RNA methylation in MOLM13 AML cells; METTL3 deficiency on gene expression and translational efficiency

2017-09-18 | GSE98623 | GEO

CUT&Tag of ARID1B and ARID2 in MOLM13 cells

Project description:MOLM13 cells were used to perform Cleavage Under Targets and Tagmentation (CUT&Tag) analysis to identify genomic binding sites of ARID1B and ARID2 in MLL-AF9 cells.

2022-03-08 | GSE188290 | GEO

Genome-wide maps of AF10( MLLT10) PZP binding in MOLM13 human AML cells

Project description:We report genomic occupancy of the AF10 PZP domain in MOLM13 cells

2020-12-15 | GSE163170 | GEO

Effect of Gilteritinib, Metformin and Combination treatments on gene expression in MOLM13-RES cells

Project description:Here, we report that Metformin shows a striking synergistic effect with Gilteritinib in suppressing cell proliferation and promoting apoptosis and cell cycle arrest in multiple FLT3-ITD AML cell lines, including FLT3 TKI-resistant MOLM13 cells. Mechanistically, the combinational treatment synergistically suppresses Polo-like kinase 1 (PLK1) expression and phosphorylation of FLT3/STAT5/ERK/mTOR in MOLM13-RES cells. Intriguingly, our retrospective clinical analysis has unveiled a significant correlation between Metformin intake and improved survival rates among FLT3-ITD AML patients. Collectively, the cotreatment of Metformin and Gilteritinib shows robustly enhanced therapeutic efficacy in treating FLT3-mutated AML by synergistically suppressing PLK1 expression and phosphorylation of FLT3/STAT5/ERK/mTOR.

2024-06-14 | GSE244855 | GEO

ChIP-seq analysis to determine p53 binding profiles in the BV173 cell line before and after treatment with the MDM2 inhibitor idasanutlin

Project description:We performed ChIP-seq analysis in order to determine the transcriptional targets of p53 in the CML cell line BV173 as a result of p53 activation using the MDM2 inhibitor idasanutlin.

2023-12-19 | GSE218182 | GEO

Analysis of gene expression in Idasanutlin-arrested SIN3A and SIN3B depleated cells

Project description:Analysis of gene expression in Idasanutlin-arrested SIN3A and SIN3B depleated cells

| PRJNA1005179 | ENA